Building Clinical Trials Capacity for Tuberculosis Drugs in High-Burden Countries
Open Access
- 6 November 2007
- journal article
- Published by Public Library of Science (PLoS) in PLoS Medicine
- Vol. 4 (11) , e302
- https://doi.org/10.1371/journal.pmed.0040302
Abstract
The long duration of TB therapy, the high prevalence of HIV coinfection, and the growing prevalence of drug-resistant TB underscore the urgent need for more effective treatments.Keywords
This publication has 6 references indexed in Scilit:
- Moxifloxacin versus Ethambutol in the First 2 Months of Treatment for Pulmonary TuberculosisAmerican Journal of Respiratory and Critical Care Medicine, 2006
- Potent Twice-Weekly Rifapentine-containing Regimens in Murine TuberculosisAmerican Journal of Respiratory and Critical Care Medicine, 2006
- Acquired Rifamycin Resistance with Twice-Weekly Treatment of HIV-related TuberculosisAmerican Journal of Respiratory and Critical Care Medicine, 2006
- Moxifloxacin-containing Regimens of Reduced Duration Produce a Stable Cure in Murine TuberculosisAmerican Journal of Respiratory and Critical Care Medicine, 2004
- Rifapentine and isoniazid once a week versus rifampicin and isoniazid twice a week for treatment of drug-susceptible pulmonary tuberculosis in HIV-negative patients: a randomised clinical trialThe Lancet, 2002
- Studies on the treatment of tuberculosis undertaken by the British Medical Research Council tuberculosis units, 1946-1986, with relevant subsequent publications.1999